Clinical Trials Logo

Rectal Cancer clinical trials

View clinical trials related to Rectal Cancer.

Filter by:

NCT ID: NCT05651971 Recruiting - Rectal Cancer Clinical Trials

The Anatomical Localization of the Inferior Mesenteric Artery in Relation to the Left Colonic Artery

Start date: November 1, 2022
Phase:
Study type: Observational

1. To observe and measure the distance between the origin of LCA (left colonic artery,LCA) and IMA (inferior mesenteric artery,IMA) root and the distance between IMA and IMV (inferior mesenteric vein,IMV) at the origin of LCA in rectal cancer patients. Statistical analysis of intraoperative measured data, on the basis of the original anatomical relationship, to achieve anatomical localization of quantitative and accurate, for the preservation of LCA laparoscopic radical resection of rectal cancer to provide a strong anatomical basis. 2. The operation time, 253 lymph node dissection time, intraoperative blood loss, postoperative anal exhaust time, postoperative feeding time, postoperative hospital stay, postoperative ischemic colitis rate and postoperative anastomotic leakage rate of patients with laparoscopic radical resection of rectal cancer with preservation of LCA were recorded. The surgical efficacy and clinical significance of laparoscopic radical resection of rectal cancer with preservation of LCA were evaluated.

NCT ID: NCT05566249 Recruiting - Rectal Cancer Clinical Trials

A Study to Validate the Safety and Feasibility of ArtiSential in Colorectal Cancer Surgery Using Prospectively Constructed Multi-center Registry

Start date: October 1, 2022
Phase:
Study type: Observational

This study is to validate the safety and feasibility of ArtiSential (Articulating laparoscopic instrument) colorectal surgery and compare it with robotic surgery for patients with rectal cancer and rectosigmoid junction cancer.

NCT ID: NCT05563922 Recruiting - Rectal Cancer Clinical Trials

Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma

OP-TNT
Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of an organ-sparing strategy after neoadjuvant chemoradiotherapy followed by transanal endoscopic microsurgery (TEM) or endoscopic local resection for early low rectal cancer(cT 1-3N0M0).Besides, the clinical complete response rate and near-clinical complete response rate, organ preservation rate, local recurrence rate, distant metastasis rate and quality of life (QoL) will also be assessed.

NCT ID: NCT05556473 Recruiting - Breast Cancer Clinical Trials

F-Tryptophan PET/CT in Human Cancers

Start date: September 29, 2022
Phase: Phase 1
Study type: Interventional

Imaging procedures such as 1-(2-[18F]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

NCT ID: NCT05538195 Recruiting - Pancreatic Cancer Clinical Trials

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Start date: June 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.

NCT ID: NCT05526079 Recruiting - Rectal Cancer Clinical Trials

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Start date: July 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.

NCT ID: NCT05523245 Recruiting - Rectal Cancer Clinical Trials

Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI

DLARC
Start date: June 24, 2022
Phase:
Study type: Observational

Establish a deep learning model based on multi-parameter magnetic resonance imaging to predict the efficacy of neoadjuvant therapy for locally advanced rectal cancer.This study intends to combine DCE with conventional MRI images for DL, establish a multi-parameter MRI model for predicting the efficacy of CRT, and compare it with the DL and non-artificial quantitative MRI diagnostic model constructed by conventional MRI to evaluate the role of DL in MRI predicting CRT. And this study also tries to build a DL platform to assess the efficacy of LARC neoadjuvant radiotherapy and chemotherapy, accurately assess patients' complete respose (pCR) after CRT, and provide an important basis for guiding clinical decision-making.

NCT ID: NCT05516641 Recruiting - Rectal Cancer Clinical Trials

Prebiotics in Rectal Cancer

Start date: July 25, 2022
Phase: N/A
Study type: Interventional

A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.

NCT ID: NCT05515796 Recruiting - Gastric Cancer Clinical Trials

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

immunotherapy,gastric cancer,rectal cancer,biomark

NCT ID: NCT05502354 Recruiting - Rectal Cancer Clinical Trials

CRP-guided Transanal Drainage Removal After Rectal Surgery

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Transanal drainage tube (TDT) has the benefit of reducing intraluminal pressure after rectal surgery and may provide ideal regional environment for anastomotic healing. Postoperative C-reactive protein (CRP) trajectory has a high negative predictive value of 0.99 for ruling out anastomotic leak (AL). Previously, TDT was removed at the surgeon's own discretion. In the present study, we design a single arm study to investigate the safety and efficacy of CRP-guided TDT removal for AL prevention following laparoscopic anterior resection for rectal carcinoma